Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Editas Medicine (EDIT)

Editas Medicine (EDIT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 107,869
  • Shares Outstanding, K 82,976
  • Annual Sales, $ 32,310 K
  • Annual Income, $ -237,090 K
  • EBIT $ -239 M
  • EBITDA $ -239 M
  • 60-Month Beta 1.88
  • Price/Sales 3.57
  • Price/Cash Flow N/A
  • Price/Book 0.85

Options Overview Details

View History
  • Implied Volatility 128.39% ( -5.05%)
  • Historical Volatility 250.48%
  • IV Percentile 82%
  • IV Rank 51.15%
  • IV High 216.03% on 02/19/25
  • IV Low 36.62% on 05/30/24
  • Put/Call Vol Ratio 0.08
  • Today's Volume 169
  • Volume Avg (30-Day) 1,229
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 36,702
  • Open Int (30-Day) 41,517

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.54
  • Number of Estimates 4
  • High Estimate -0.41
  • Low Estimate -0.73
  • Prior Year -0.76
  • Growth Rate Est. (year over year) +28.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2400 +2.42%
on 03/26/25
2.2900 -44.54%
on 02/27/25
-0.5700 (-30.98%)
since 02/26/25
3-Month
1.1200 +13.39%
on 02/11/25
3.2999 -61.51%
on 02/19/25
+0.0400 (+3.25%)
since 12/26/24
52-Week
1.1200 +13.39%
on 02/11/25
7.5300 -83.13%
on 03/27/24
-5.9500 (-82.41%)
since 03/26/24

Most Recent Stories

More News
Editas Medicine Announces Chief Financial Officer Transition

EDIT : 1.2700 (-2.31%)
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential

The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027.

IBB : 131.14 (-1.38%)
EDIT : 1.2700 (-2.31%)
VTI : 281.16 (-1.17%)
IWM : 205.59 (-1.02%)
Editas: Q4 Earnings Snapshot

Editas: Q4 Earnings Snapshot

EDIT : 1.2700 (-2.31%)
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

EDIT : 1.2700 (-2.31%)
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

EDIT : 1.2700 (-2.31%)
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

EDIT : 1.2700 (-2.31%)
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

EDIT : 1.2700 (-2.31%)
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Shares of Editas Medicine EDIT plunged 23.8% on Dec. 13 after it announced a strategic decision to end the development of its lead gene editing therapy, reni-cel, following the failure of an extensive...

CTMX : 0.5941 (-3.41%)
CSTL : 20.08 (-3.65%)
EDIT : 1.2700 (-2.31%)
SPRO : 0.8900 (-1.00%)
Editas Medicine Advances In Vivo CRISPR-Edited Medicines, Announces Workforce Reduction and Strategic Transition

Editas Medicine announces advancements in in vivo CRISPR gene editing, optimizing costs, and reducing workforce while focusing on hematologic diseases.Quiver AI SummaryEditas Medicine, Inc. has announced...

EDIT : 1.2700 (-2.31%)
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

EDIT : 1.2700 (-2.31%)

Business Summary

Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company's discovery efforts target...

See More

Key Turning Points

3rd Resistance Point 1.3767
2nd Resistance Point 1.3433
1st Resistance Point 1.3067
Last Price 1.2700
1st Support Level 1.2367
2nd Support Level 1.2033
3rd Support Level 1.1667

See More

52-Week High 7.5300
Fibonacci 61.8% 5.0814
Fibonacci 50% 4.3250
Fibonacci 38.2% 3.5686
Last Price 1.2700
52-Week Low 1.1200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar